期刊文献+

舒洛地特联合草木犀流浸液片对下肢深静脉血栓后遗症的防治效果 被引量:1

Effect of oral sulodexide combined with melilotus extract tablet on deep venous thrombosis-related post-thrombotic syndrome
下载PDF
导出
摘要 目的探讨口服舒洛地特联合草木犀流浸液片对下肢深静脉血栓后遗症的防治效果。方法选取我院2015年3月至2015年12月门急诊接诊门急诊应用舒洛地特治疗下肢深静脉血栓后遗症的患者共42例。最后,共34例患者纳入研究,将18例口服舒洛地特联合草木犀流浸液片的患者设定为观察组,而单用草木犀流浸液片的16例为对照组,并按Villalta’s评分项目进行观察研究。结果观察组对患者的下肢主观症状包括症状性疼痛、感觉异常(下肢沉重,麻木,骚痒症等不适)改善的有效率相对于对照组显示出了显著的统计学差异(症状性疼痛:14/77.78%vs 6/37.5%,P=0.016;感觉异常:14/77.78%vs 7/43.75%,P=0.040)。但客观性指标仅有下肢发红或腓肠肌压痛显示出了显著的效果(15/83.33%vs 4/25%,P<0.001)。结论舒洛地特联合草木犀流浸液片对下肢深静脉血栓后遗症治疗效果是可靠且相对安全的。 Objective To explore the effect of oral sulodexide combined with melilotus extract tablet on post-thrombotic syndrome (PTS). Methods Thirty-four cases with PTS were included in the study from March 2015 to December 2015, in which 18 cases were treated with oral sulodexide combined with melilotus extract tablet (observation group) and 16 were taken melilotus extract tablet alone. The clinical effect was evaluated by the Villalta ’s score. Results The therapeutic effect of subjective symptoms in the suffering limbs, such as symptomatic pain and paresthesia (heaviness, numbness, itching and discomfort) in the observation group had a great improvement as compared with the control group (symptomatic pain: 14/77.78% vs 6/37.5%, P=0.016; paresthesia: 14/77.78% vs 7/43.75%, P=0.040). The objective indicators, including skin irritation and redness, tenderness of gastrocnemius muscle also showed obvious improvement (4/25%, 15/83.33%vs P=0.01). Conclusion Oral sulodexide combined with melilotus extract tablet can facilitate post-thrombotic syndrome to achieve better clinical effect.
出处 《岭南现代临床外科》 2016年第4期487-489,共3页 Lingnan Modern Clinics in Surgery
关键词 舒洛地特 下肢深静脉血栓后遗症 Villalta’s 评分 Sulodexide Post-thrombotic syndrome Villalta’s scoring
  • 相关文献

参考文献10

  • 1Kolbach DN, Neumann HA, Prins MH. Definition of the post- thrombotic syndrome, differences between existing elassifications [J]. Eur J Vase Endovase St~rg, 2005, 30(4): 404-414.
  • 2Prandoni P, Kahn SR. Post-thrombotic syndrome : prevalence, prognostication and need for progress [J]. Br J Haematol, 2009, 145(3): 286-295.
  • 3Carman TL. Prevention of the post-thrombotic syndrome [J]. Curr Treat Options Cardiovasc Med, 2016, 18(8) : 51.
  • 4Galanaud JP, Kahn SR. Postthrombotic syndrome: a 2014 update [J]. Curr Opin Cardiol, 2014, 29(6): 514-519.
  • 5Andreozzi GM. Sulodexide in the treatment of chronic venous disease [J]. Am J Cardiovasc Drugs, 2012, 12(2): 73-81.
  • 6Luzzi R, Belcaro G, Dugall M, et al. The efficacy of sulodexide in the prevention of postthrombotic syndrome [J]. Clin Appl Thromb Hemost, 2014, 20(6): 594-599.
  • 7Soosainathan A, Moore HM, Gohel MS, et al. Scoring systems for the post-thrombotic syndrome [J]. J Vasc Surg, 2013, 57(1): 254-261.
  • 8Kahn SR, Galanaud JP, Vedantham S, et al. Guidance for the prevention and treatment of the post-thrombotic syndrome [J]. J Thromb Tbrombolysis, 2016, 41(1): 144-153.
  • 9Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo- controlled trial [J]. Lancet, 2014, 383(9920): 880-888.
  • 10Urbanek T, Krasinski Z, Sumihska-Jasifiska K, et al. Sulodexide reduces the inflammatory reaction and senescence of endothelial cells in conditions involving chronic venous disease [J]. Int Angiol, 2016, 35(2): 140-147.

同被引文献9

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部